ghk-cu dosage per kg or weight based GLOW Peptide & Protocol Guide GHK-Cu Peptides Before and After:

A TSAR of 26.5% means more than a quarter of the bald area was restored

In pulmonary fibrosis studies using bleomycin to induce lung injury in mice, GHK-Cu doses of 0.0026 to 0.26 mg/mL/day administered every other day reduced inflammatory cell infiltration, decreased interstitial thickness (the scarring that stiffens lung tissue), and lowered TNF-alpha and IL-6 expression

Both peptides clear from serum within 68 hours, but tissue retention times differ slightly: GHK-Cu persists 2472 hours in collagen-rich tissue (dermis, tendon), while AHK-Cu shows preferential retention in elastin-rich tissue (vascular walls, lung parenchyma)

It is not approved for therapeutic use and is available solely for experimental and laboratory research

In a 1992 study in rats, the major finding was that intraperitoneal DSIP injection increased the concentration of substance P a neurotransmitter positively correlated with the regulation of anxiety and mood15 in the hypothalamus, suggesting to the researchers that the peptide sharply decreases the classical manifestations of stress.16 Earlier studies in humans, namely a series of five trials published in 1983, came to similar conclusions, with better relaxation and apparently improved tolerance against psychic stress reported by the subjects.17 Its possible that the improved stress and anxiety markers were consequent to DSIP-associated sleep enhancements.18 Substance use recovery A study from 1984 published in European Neurology describes DSIPs potential use as a treatment for alcohol and opiate use disorders

It directly activates fibroblasts, the cells responsible for producing collagen and other structural proteins